SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI is trending as the community rallies around its status as the leading cat-themed meme coin on the Base chain, with active discussions focused on ecosystem expansion and integration with AI utilities. Investors are closely monitoring volume and technical support levels, expressing high conviction in a potential rebound through long-term holding and strategic accumulation.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is facing intense downward pressure driven by a mix of heavy insider selling, technical selling, and broader market concerns regarding data center saturation and increased competition from hyperscalers. While many investors remain focused on the company's significant revenue backlog and strong long-term demand for AI infrastructure, the stock's recent volatility has triggered significant debate among the community regarding whether the current price represents a capitulation bottom or a deeper structural reset.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

$TRUMP.X is experiencing heightened volatility and intense community debate as supporters anticipate potential catalysts related to the Clarity Act and the upcoming national anniversary, while skeptics point to the token's significant decline from its all-time highs and ongoing concerns about its long-term utility. The conversation remains sharply divided between investors highlighting potential short-squeeze opportunities and those warning against the risks of participating in a project they characterize as a speculative, brand-driven endeavor.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is facing significant selling pressure as investors react to speculative threats from Starlink and recent management turnover, leading to concerns about the company's competitive positioning in the wireless and broadband sectors. Despite these challenges, the community is actively debating the stock's long-term value, with many bulls focusing on its defensive nature, consistent dividend payments, and ongoing infrastructure investments as reasons to accumulate shares at current levels.

Chip

Chip is generating significant buzz as investors debate its role as a potential financing layer for AI infrastructure, with bulls highlighting its GPU-backed lending model and bears questioning the token's volatility and supply structure. The community remains deeply divided, with active discussion focused on the project's real-world utility compared to typical crypto narratives and speculative momentum.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is attracting significant community attention due to its breakthrough Alpha DaRT oncology platform and a recently finalized strategic partnership with Tolmar, which investors view as a massive validation of the technology's clinical potential. Discussion is heavily focused on upcoming clinical catalysts, including the highly anticipated data presentation at the AHNS conference, with many participants framing the stock as a long-term play in the evolving standard of care for solid tumors.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as investors monitor the upcoming April 29th Supreme Court oral arguments in the Hikma patent case and the company's Q1 financial results on the same day. The community remains focused on potential M&A outcomes, the strategic value of the LR-EtEPA platform, and significant skepticism regarding management's ability to drive shareholder value.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is facing heavy selling pressure following an FDA Complete Response Letter for its Hunter syndrome gene therapy, which rejected the BLA due to trial design and surrogate endpoint concerns. The investment community is now debating the company's cash runway and future development path, as they shift focus to upcoming clinical data readouts for other programs.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment focuses on branded generic pharmaceuticals that are manufactured worldwide and marketed and sold outside the United States, primarily in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternative care testing sites. The Nutritional Products segment oversees the worldwide sale of pediatric and adult nutritional products. The Medical Devices segment offers a broad range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as diabetes care and continuous glucose monitoring products. It also provides neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott Laboratories is experiencing significant volatility and heavy volume as investors digest a positive Q2 earnings beat and raised full-year guidance, which has spurred debate over the stock's valuation and its potential for a turnaround. The community is actively discussing the stock's role as a defensive healthcare play amid broader market rotations and ongoing sentiment around its recent strategic acquisitions.

Robinhood Ventures Fund I engages in investing in companies located in the United States. It focuses on a broad range of sectors and industries. It provides financing for early-stage transactions. The company was founded on August 22, 2025 and is headquartered in Menlo Park, CA.

Robinhood Ventures Fund I - Common shares of beneficial interest

Robinhood Ventures Fund I is currently facing significant volatility as investors debate the impact of its underlying private equity holdings, including major AI and aerospace firms, against its recent share price fluctuations. The community is actively tracking the fund's NAV, speculating on upcoming IPO potential for its portfolio companies, and reacting to varying margin requirements and institutional inflow trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RBC Capital Reaffirms Outperform Rating For Verastem (VSTM)

RBC Capital Reaffirms Outperform Rating For Verastem (VSTM...

Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains?

Verastem (VSTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new employees and the grant of stock options to purchase 91,000 shares of its...

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive preliminary data from the ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375, an investigational oral KRAS...

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients...

Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial (NCT07644559) evaluating VS-7375, an...

Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor conference call and webcast on Tuesday, June 23 at 4:30 pm ET to report progress across the VS-7375 oral...

VSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug — Retail Eyes The Next Keytruda 

Equity

The Fast Track designation is designed to help promising medicines for serious diseases reach patients faster by allowing more frequent contact with regulators and potentially quicker review.


Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to VS-7375, an oral and potential...

Verastem Oncology to Present at Jefferies Healthcare Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is pacing for a losing week as a semiconductor ($SMH) sell-off has dragged the market lower amid growing doubts about AI spending. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.43	--	--	N/A
Q1 '26	-$0.47	-$0.37	20.43%	BEAT
Q4 '25	-$0.52	-$0.39	25.36%	BEAT
Q3 '25	-$0.62	-$1.35	-117.35%	MISSED
Q2 '25	-$0.73	-$0.39	46.41%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

VSTMVerastem Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest VSTM News